Fidaxomicin to Prevent Clostridium Difficile Colonization

• Status: Withdrawn
• Trial end date: 2013-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this research study is to evaluate the effectiveness of an antibiotic called fidaxomicin in preventing C. difficile infection.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Washington University School of Medicine
• Collaborator: Centers for Disease Control and Prevention
• Treatments: Fidaxomicin

Criteria

Inclusion Criteria:

• ≥ 18 years old

• On broad spectrum antimicrobials

• Anticipated length of stay of > 48 hours after enrollment

• A non-ICU inpatient

Exclusion Criteria:

• Pregnant

• Expected to die within 7 days

• Have previously been enrolled in this trial or a trial of an investigational agent to treat CDI, and/or are on monotherapy with an antimicrobial generally considered not to increase the risk of CDI (vanc, macrolides, tetracyclines, trimethoprim/sulfamethoxazole, aminoglycosides, colistin, linezolid, nitrofurantoin, metronidazole)